111 related articles for article (PubMed ID: 25012943)
21. Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.
Srinivas U; Barwad A; Pubbaraju SV
Br J Haematol; 2014 Jun; 165(5):583. PubMed ID: 24456122
[No Abstract] [Full Text] [Related]
22. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.
Metzgeroth G; Schwaab J; Gosenca D; Fabarius A; Haferlach C; Hochhaus A; Cross NC; Hofmann WK; Reiter A
Leukemia; 2013 Nov; 27(11):2254-6. PubMed ID: 23615556
[No Abstract] [Full Text] [Related]
23. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
24. Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit).
Moawad EY
J Gastrointest Cancer; 2015 Sep; 46(3):272-83. PubMed ID: 25985771
[TBL] [Abstract][Full Text] [Related]
25. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
26. "Likely to be missed if unsuspected":
Sharma P; Khaire NS; Sreedharanunni S; Malhotra P; Varma N
J Cancer Res Ther; 2022; 18(1):316-317. PubMed ID: 35381811
[No Abstract] [Full Text] [Related]
27. PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.
Andrei M; Bandarchuk A; Abdelmalek C; Kundra A; Gotlieb V; Wang JC
Am J Case Rep; 2017 Feb; 18():173-180. PubMed ID: 28209946
[TBL] [Abstract][Full Text] [Related]
28. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
29. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
[No Abstract] [Full Text] [Related]
30. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
[TBL] [Abstract][Full Text] [Related]
31. Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene.
Yoshida M; Tamagawa N; Nakao T; Kanashima H; Ueda H; Murakami A; Yorifuji T; Yamane T
Leuk Lymphoma; 2015 Mar; 56(3):768-9. PubMed ID: 24975316
[No Abstract] [Full Text] [Related]
32. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
33. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
[TBL] [Abstract][Full Text] [Related]
34. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
Milovancev M; Helfand SC; Marley K; Goodall CP; Löhr CV; Bracha S
BMC Vet Res; 2016 Jun; 12():85. PubMed ID: 27259510
[TBL] [Abstract][Full Text] [Related]
35. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.
Vaklavas C; Tefferi A; Butterfield J; Ketterling R; Verstovsek S; Kantarjian H; Pardanani A
Leuk Res; 2007 May; 31(5):691-4. PubMed ID: 17095087
[TBL] [Abstract][Full Text] [Related]
36. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
37. Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response?
Pitini V; Arrigo C; Altavilla G; Naro C; Righi M
Leuk Res; 2007 May; 31(5):725-6. PubMed ID: 16978696
[No Abstract] [Full Text] [Related]
38. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
Ng HJ; Tan DC; Yiu RC; How GF
Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
[TBL] [Abstract][Full Text] [Related]
39. Platelet-derived growth factor receptor alpha (PDGFRα) is overexpressed in NK/T-cell lymphoma and mediates cell survival.
Lu L; Fu X; Li Z; Qiu Y; Li W; Zhou Z; Xue W; Wang Y; Jin M; Zhang M
Biochem Biophys Res Commun; 2018 Oct; 504(2):525-531. PubMed ID: 30201265
[TBL] [Abstract][Full Text] [Related]
40. The results of imatinib therapy for patients with primary eosinophilic disorders.
Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J
Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]